3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
3
Genitourinary
3
Head & Neck
2
Gastrointestinal
2
Sarcoma
1
Other solid neoplasm
1
NET
1
Gynecologic
1
Endocrine
1
Dermatologic
1
CNS
1
Breast
1
Conditions
Gastrointestinal Stromal Tumors
17
Sarcoma
6
Sarcoma, Ewing
5
Osteosarcoma
5
Neoplasm Metastasis
4
Rhabdomyosarcoma
3
Colorectal Neoplasms
3
Mesothelioma, Malignant
2
Hemangiosarcoma
2
Chondrosarcoma
2
Bone Neoplasms
2
Wilms Tumor
1
Turcot syndrome
1
Triple Negative Breast Neoplasms
1
Thyroid Neoplasms
1
Thymoma
1
Tertiary Lymphoid Structures
1
Stomach Neoplasms
1
Small Cell Lung Carcinoma
1
Piebaldism
1
Patient Compliance
1
Pathologic Complete Response
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Neuroblastoma
1
Neoplasms
1
Melanoma
1
Liposarcoma
1
Leiomyosarcoma
1
Histiocytoma, Malignant Fibrous
1
Interventions
Nivolumab
5
Magnetic Resonance Spectroscopy
5
Specimen Handling
4
pembrolizumab
2
Ipilimumab
2
Immunoglobulin G
2
tislelizumab
1
temsirolimus
1
spartalizumab
1
sargramostim
1
regorafenib
1
pemigatinib
1
eribulin
1
cabozantinib
1
brivanib
1
avelumab
1
X-Rays
1
Valproic Acid
1
Sirolimus
1
Radiosurgery
1
Mifepristone
1
Fluorodeoxyglucose F18
1
FAPI-46
1
Docetaxel
1
Disulfides
1
Cyclophosphamide
1
Cryosurgery
1
Colony-Stimulating Factors
1
Clinical Trials, Phase II as Topic
1
Cetuximab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Carcinoma, Transitional Cell
×
regorafenib
×
Sarcoma
×
Clear all
NCT03475953
2023-03-03
REGOMUNE
Institut Bergonié
Phase 1/2
Unknown
747 enrolled